Combined pulmonary fibrosis and emphysema syndrome: the age of majority
- PMID: 38575167
- DOI: 10.1183/13993003.00353-2024
Combined pulmonary fibrosis and emphysema syndrome: the age of majority
Conflict of interest statement
Conflict of interest: V. Cottin reports grants from Boehringer Ingelheim, consulting fees from AstraZeneca, Boehringer Ingelheim, BMS/Celgene, CSL (Behring, Vifor), Ferrer/United Therapeutics, GSK, Pliant, PureTech, RedX, Roche, Sanofi, Shionogi and Vifor, payment or honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Ferrer/United Therapeutics, Roche and Sanofi, support for attending meetings from Boehringer Ingelheim and Sanofi, participation on a data safety monitoring board or advisory board for Galapagos, Galecto, GSK and Molecure, and an adjudication committee role for Fibrogen.
Comment on
-
Mortality surrogates in combined pulmonary fibrosis and emphysema.Eur Respir J. 2024 Apr 4;63(4):2300127. doi: 10.1183/13993003.00127-2023. Print 2024 Apr. Eur Respir J. 2024. PMID: 37973176 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical